The Complete Response to Targeted Drugs Without Surgery or Radiotherapy: A Case of Pituitary Metastasis From Renal Cell Carcinoma
- PMID: 27832697
The Complete Response to Targeted Drugs Without Surgery or Radiotherapy: A Case of Pituitary Metastasis From Renal Cell Carcinoma
Abstract
Pituitary gland metastasis was seen in elderly patients, and the incidence of pituitary metastasis is 1% to 4% of all cancer patients. Renal cell carcinoma is a primary malignancy in only 2.6% of pituitary metastases. We reported a 50-year-old man with pituitary metastasis from renal cell carcinoma that had signs of diabetes insipidus. He had multiple lesions in both lungs, and bone scan involved L12 and L1 vertebrates. He was treated with combination bevacizumab 600 mg/month and sunitinib 50 mg/D for four weeks with two weeks rest for 6 months. Treatment with targeted drugs without surgery of pituitary or radiotherapy improved metastatic renal cell carcinoma in the patient.
Keywords: Diabetes insipidus; Pituitary metastasis; Renal cell carcinoma; Sunitinib.
Similar articles
-
Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.Am J Case Rep. 2017 Jan 3;18:7-11. doi: 10.12659/ajcr.901032. Am J Case Rep. 2017. PMID: 28044054 Free PMC article.
-
Metastatic renal cell carcinoma to the pituitary gland presenting with hypopituitarism.J Endocrinol Invest. 1992 Oct;15(9):677-81. doi: 10.1007/BF03345815. J Endocrinol Invest. 1992. PMID: 1479150 Review.
-
Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.Anticancer Drugs. 2010 Feb;21(2):210-3. doi: 10.1097/CAD.0b013e3283340d1f. Anticancer Drugs. 2010. PMID: 19952729
-
Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.J Clin Oncol. 2011 Mar 20;29(9):e241-2. doi: 10.1200/JCO.2010.33.4375. Epub 2011 Jan 18. J Clin Oncol. 2011. PMID: 21245426 No abstract available.
-
Tolerability of first-line therapy for metastatic renal cell carcinoma.Cancer Treat Rev. 2009 May;35(3):297-307. doi: 10.1016/j.ctrv.2008.12.003. Epub 2009 Feb 26. Cancer Treat Rev. 2009. PMID: 19249157 Review.
Cited by
-
Current status and treatment modalities in metastases to the pituitary: a systematic review.J Neurooncol. 2020 Jan;146(2):219-227. doi: 10.1007/s11060-020-03396-w. Epub 2020 Jan 13. J Neurooncol. 2020. PMID: 31933258
-
An unsuspected complication with immune checkpoint blockade: a case report.J Med Case Rep. 2018 Sep 4;12(1):246. doi: 10.1186/s13256-018-1782-0. J Med Case Rep. 2018. PMID: 30176934 Free PMC article.
-
Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review.Front Oncol. 2021 Nov 17;11:773905. doi: 10.3389/fonc.2021.773905. eCollection 2021. Front Oncol. 2021. PMID: 34869016 Free PMC article. Review.
-
Twelve cases of pituitary metastasis: a case series and review of the literature.Pituitary. 2018 Oct;21(5):463-473. doi: 10.1007/s11102-018-0899-x. Pituitary. 2018. PMID: 29974330 Review.
-
Pituitary metastasis: a rare condition.Endocr Connect. 2018 Oct;7(10):1049-1057. doi: 10.1530/EC-18-0338. Endocr Connect. 2018. PMID: 30139817 Free PMC article.
